C9orf72-mediated ALS and FTD: multiple pathways to disease
R Balendra, AM Isaacs - Nature Reviews Neurology, 2018 - nature.com
The discovery that repeat expansions in the C9orf72 gene are a frequent cause of
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has revolutionized …
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has revolutionized …
C9ORF72: what it is, what it does, and why it matters
J Smeyers, EG Banchi, M Latouche - Frontiers in cellular …, 2021 - frontiersin.org
When the non-coding repeat expansion in the C9ORF72 gene was discovered to be the
most frequent cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis …
most frequent cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis …
Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives
T Bonifacino, RA Zerbo, M Balbi, C Torazza… - International journal of …, 2021 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal, multigenic, multifactorial, and non-cell
autonomous neurodegenerative disease characterized by upper and lower motor neuron …
autonomous neurodegenerative disease characterized by upper and lower motor neuron …
Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease
PA Gelon, PA Dutchak, CF Sephton - Frontiers in Molecular …, 2022 - frontiersin.org
Synaptic loss is a pathological feature of all neurodegenerative diseases including
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is a disease of …
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is a disease of …
Modelling amyotrophic lateral sclerosis in rodents
TW Todd, L Petrucelli - Nature Reviews Neuroscience, 2022 - nature.com
The efficient study of human disease requires the proper tools, one of the most crucial of
which is an accurate animal model that faithfully recapitulates the human condition. The …
which is an accurate animal model that faithfully recapitulates the human condition. The …
Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with an extremely
heterogeneous clinical and genetic phenotype. In our efforts to find therapies for ALS, the …
heterogeneous clinical and genetic phenotype. In our efforts to find therapies for ALS, the …
Molecular Mechanisms of Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion
M Babić Leko, V Župunski, J Kirincich… - Behavioural …, 2019 - Wiley Online Library
Two clinically distinct diseases, amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD), have recently been classified as two extremes of the FTD/ALS spectrum …
dementia (FTD), have recently been classified as two extremes of the FTD/ALS spectrum …
Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD
A Starr, R Sattler - Brain research, 2018 - Elsevier
Amyotrophic lateral sclerosis (ALS) is characterized by a progressive degeneration of upper
and lower motor neurons, resulting in fatal paralysis due to denervation of the muscle. Due …
and lower motor neurons, resulting in fatal paralysis due to denervation of the muscle. Due …
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges
L Zhu, S Li, XJ Li, P Yin - Translational neurodegeneration, 2023 - Springer
In order to dissect amyotrophic lateral sclerosis (ALS), a multigenic, multifactorial, and
progressive neurodegenerative disease with heterogeneous clinical presentations …
progressive neurodegenerative disease with heterogeneous clinical presentations …
[HTML][HTML] NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS
J Jiménez-Villegas, L Ferraiuolo, RJ Mead… - Free Radical Biology …, 2021 - Elsevier
Abstract Amyotrophic Lateral Sclerosis (ALS) is a devastating heterogeneous disease with
still no convincing therapy. To identify the most strategically significant hallmarks for …
still no convincing therapy. To identify the most strategically significant hallmarks for …